Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Ronald P. DeMatteo(Memorial Sloan Kettering Cancer Center), Karla V. Ballman(Mayo Clinic in Arizona), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Peter W. T. Pisters(The University of Texas MD Anderson Cancer Center), George D. Demetri(Dana-Farber Cancer Institute), Martin E. Blackstein(Mount Sinai Hospital), Charles D. Blanke(BC Cancer Agency), Margaret von Mehren(Fox Chase Cancer Center), Murray F. Brennan(Memorial Sloan Kettering Cancer Center), Shreyaskumar Patel(The University of Texas MD Anderson Cancer Center), Martin D. McCarter(University of Colorado Denver), Jonathan Polikoff(Kaiser Permanente), Benjamin Tan(Washington University in St. Louis), Kouros Owzar(Duke University)
The Lancet
March 1, 2009
Cited by 1,358Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis